Drug Profile
Retinitis pigmentosa gene therapy - Staidson Beijing Biopharmaceuticals
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Staidson Beijing BioPharmaceuticals
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Retinitis pigmentosa
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Retinitis pigmentosa in China (unspecified route) prior to September 2023 (Staidson Beijing BioPharmaceuticals pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in China
- 07 Jul 2016 Preclinical trials in Retinitis pigmentosa in China (unspecified route)